Post by Ardigen

The conversation around AI in drug discovery is getting more practical - and more operational. The focus is no longer only on what AI could do, but on how teams can validate it, deploy it, manage costs, and turn existing data into better decisions. In Ardigen Bulletin #2, we cover: - takeaways from BIO International Convention and Digital Health Innovations Forum - recent AI biotech news on toxicity detection, pathology-based biomarkers, and antibody design - Ardigen Knowledge Hub articles on knowledge graphs and BBB-penetrating antibodies - practical AI tips for working with agents and LLM-based tools Read the second edition below and subscribe for monthly AI drug discovery insights. #AIDrugDiscovery #DrugDiscovery #Biotech #Pharma #LifeSciences #AIinPharma #Bioinformatics #Biomarkers